1. Home
  2. GLU vs CNTB Comparison

GLU vs CNTB Comparison

Compare GLU & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

N/A

Current Price

$19.27

Market Cap

116.1M

Sector

Finance

ML Signal

N/A

Logo Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

N/A

Current Price

$2.45

Market Cap

135.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GLU
CNTB
Founded
2004
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.1M
135.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GLU
CNTB
Price
$19.27
$2.45
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
7.5K
359.3K
Earning Date
01-01-0001
08-13-2026
Dividend Yield
8.60%
N/A
EPS Growth
N/A
N/A
EPS
0.62
N/A
Revenue
N/A
$64,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.24
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.68
$1.23
52 Week High
$21.69
$3.82

Technical Indicators

Market Signals
Indicator
GLU
CNTB
Relative Strength Index (RSI) 51.20 53.93
Support Level $19.32 $2.27
Resistance Level $19.66 $2.69
Average True Range (ATR) 0.21 0.16
MACD -0.00 0.01
Stochastic Oscillator 44.26 50.94

Price Performance

Historical Comparison
GLU
CNTB

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Share on Social Networks: